Posted by AGORACOM-JC
at 4:09 PM on Friday, October 30th, 2020
Else Nutrition Holdings which develops plant-based alternatives to dairy milk-based baby foods, announces the early availability of its innovative products in US retail stores. The company expects to begin first retail sales through KeHE distributors in the western and southern regions of the United States as early as the end of November 2020.
Else began trading on the Toronto exchange last June and saw huge stock market interest upon its launch, being touted as hot stock to watch, in its plans to disrupt dairy nutrition for infants. Else says thats its products are the first viable choice other than dairy and soy in in this category for over 120 years.
Up to four regional customers and one national key account, for a total of 380 shops, will be served before the start of the Christmas season, following the recent successful launch of its plant-based baby food products through its online store and via Amazon. Else is now working diligently through a network of food brokers and KeHE sales partners to acquire strategic customers in the stationary trade in various key regions of the USA.
“The lively interest in our product makes us very optimistic. Parents and families have long been waiting for a plant-based alternative to milk-based baby food. Soon, parents across the United States will be able to buy our product in a shop near them and also order it through online retailing,” said Hamutal Yitzhak, CEO and founding member of Else.
Posted by AGORACOM-JC
at 6:04 PM on Thursday, October 29th, 2020
SPONSOR: Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) Innocan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. In addition, the company filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis.
“The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027.
Could Cannabis Eliminate The High-Cost And High-Stakes Of Current Psoriasis Medicines?
Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol.
The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.”
A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis.
Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.
The National Psoriasis Foundation states that upwards of 8 million people have the auto-immune skin disorder. Often accompanied by arthritis, psoriasis not only causes scaling of the skin, but complications to fingernails as well.
Affecting everyone from children to adults, psoriasis can lead to anxiety and depression, as individuals with the skin disorder are often afraid of being ridiculed. Usually treated with Humira and Enbrel, psoriasis comes with a shocking price tag and complications that are often difficult to ignore.
A 2014 study published in the journal Drugs in Context found that Humira had a price tag upwards of $39,000, while Enbrel’s annual cost was around $46,000. Stelara, the most expensive drug, was found to cost over $53,000. As TNF blockers, while medications like Humira help against psoriasis, they can lower the body’s ability to fight infections and cause serious side effects.
Even more interesting, a September 2019 study in London found that, “A number of medications commonly prescribed by rheumatologists may interact with cannabidiol oil” (CBD oil). The most affected medicines appear to be corticosteroids (including hydrocortisone and prednisolone) since CBD, “is a potent inhibitor of CYP3A.” Put plainly, CBD may block the effects of the other medicine.
Image Credit: Aleksandr_Kravtsov | Getty Images via The Fresh Toast
Can CBD alone help psoriasis?
Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol. The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.”
A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis. Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.
While CBD and cannabis offer pain relief and psoriasis is often accompanied by rheumatoid arthritis, each individual must discuss the addition of any new medicine (including CBD and cannabis) with their care team. With new clinical trials for cannabinoids and psoriasis recruiting even now, promising cures may be on the horizon.
Posted by AGORACOM-JC
at 7:39 AM on Thursday, October 29th, 2020
Else has successfully completed a second commercial manufacturing run, 300% larger than the initial production run, and will commence a third manufacturing run in early November
This planned production run is expected to be 200% larger than the second run, and 600% larger than the inaugural one
Successful scale-up of production while maintaining a consistent and high-quality product is a major inflection point in the Company’s go-to market strategy
Else will generate additional inventory to service the Company’s expansion in the U.S. market as it rapidly expands into retail distribution, and scales its online sales
VANCOUVER, BC , Oct. 29, 2020 – ELSE NUTRITION HOLDINGS INC. (TSX-V: BABY) (OTCQX: BABYF) (FSE: 0YL) (” Else ” or the ” Company “), a commercial stage developer of plant-based alternatives to dairy-based baby nutrition, is pleased to provide an update on its North American product launch of its plant-based Toddler Nutrition product.
Else has successfully completed a second commercial manufacturing run, 300% larger than the initial production run, and will commence a third manufacturing run in early November. This planned production run is expected to be 200% larger than the second run, and 600% larger than the inaugural one. Successful scale-up of production while maintaining a consistent and high-quality product is a major inflection point in the Company’s go-to market strategy. As a result, Else will generate additional inventory to service the Company’s expansion in the U.S. market as it rapidly expands into retail distribution, and scales its online sales.
“We are encouraged by the early response to our long awaited product launch, and equally pleased to have to ramp up our inventory as we continue to see strong demand for our novel, clean-label, plant-based Toddler Nutrition product,” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else. “We are grateful for the very positive daily feedback from parents across North America , and look forward to bringing the product to store shelves soon. Additionally, a consistent, high quality and scalable manufacturing process is a critical pillar of our business – we are pleased to have successfully completed two commercial scale runs and look forward to exponentially scaling the next one.
Else has completed the setup and order automation processes by signing up with a third-party logistics company. This provider has warehouses across the U.S. and Canada which will support Else’s E-commerce sales. Online order shipments have already commenced.
Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com , and on Amazon.com. The Company also recently added subscription plans on its e-store.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 7:29 AM on Thursday, October 29th, 2020
Alen Paul Silverrstieen, CEO of ImagineAR, will be speaking at the Global XR Bootcamp 2020
The Online Global XR Bootcamp 2020 will be the biggest online Virtual, Augmented and Mixed Reality event in the world and will be hosted November 13 th -14 th , 2020
The event will consist of a 24-hour live stream of high-quality sessions by global speakers planned around the world through all the time zones
VANCOUVER, BC and ERIE, Pa. , Oct. 29, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create their own mobile phone AR campaigns, is pleased to announce that Alen Paul Silverrstieen, CEO of ImagineAR, will be speaking at the Global XR Bootcamp 2020. The Online Global XR Bootcamp 2020 will be the biggest online Virtual, Augmented and Mixed Reality event in the world and will be hosted November 13 th -14 th , 2020. The event will consist of a 24-hour live stream of high-quality sessions by global speakers planned around the world through all the time zones.
Mr. Silverrstieen will be specifically addressing the utilization of mobile augmented reality for sports fan engagement and activation.
Alen Paul stated; “ImagineAR is expanding globally and this online event will provide the opportunity to introduce our augmented reality platform and mobile app SDK plugin to a new audience. We have recently started marketing programs in the UK and Middle East. Interest in utilizing AR for fan engagement has been growing in today’s new Covid-19 environment and we are excited to be launching the Valencia FC program this year.”
This press release is available on the Company’s AGORACOM Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
About Global XR BootCamp
The Online Global XR Bootcamp 2020 will be the biggest online Virtual, Augmented and Mixed Reality event in the world. The event will consist of a 24-hour live stream of high quality sessions by global speakers planned around the world through all the time zones. Organizers have the ability to organize an online meetup in virtual reality as a community gathering. Watch content about virtual reality, augmented reality, mixed reality, WebXR and related technologies like machine learning and AI brought to you by local heroes, or just stop by to meet with others from the local community. https://www.globalxrbootcamp.com/
About ImagineAR
ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.
All trademarks of the property of respective owners.
ON BEHALF OF THE BOARD
Alen Paul Silverrstieen President & CEO (818) 850-2490
We encourage you to do your own due diligence and ask your broker if ImagineAR IInc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by ImagineAR management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 1:47 PM on Wednesday, October 28th, 2020
SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. In addition, the company signed a two-year agreement with Valencia C.F. of La Liga to provide interactive Augmented Reality experiences for almost 7 million fans around the world. Learn More.
AR isn’t just ‘exciting’, it’s practical
Augmented reality might seem like a daunting new frontier for the average business, but adopting this new technology is a lot easier than it seems
With an anticipated 3.8 billion smartphone users in 2021, more people are using mobile tech to experience the world, from enhanced museum tours to Animoji
If you haven’t already considered it, AR can be a smart, practical form of smart marketing and branding.
Augmented reality might seem like a daunting new frontier for the average business, but adopting this new technology is a lot easier than it seems. With an anticipated 3.8 billion smartphone users in 2021, more people are using mobile tech to experience the world, from enhanced museum tours to Animoji. If you haven’t already considered it, AR can be a smart, practical form of smart marketing and branding.
First, it’s important to distinguish between augmented reality and virtual reality. Virtual reality is an almost wholly-digital experience that requires special hardware to immerse yourself in a new environment. Augmented reality is a combination of the digital and physical worlds, where the former is often “layered” over the latter. If you’ve used custom Snapchat filters or played Pokemon Go, you’ve already tried AR without even realizing it.
But the great thing about AR is that it doesn’t require buying new hardware. Virtual reality, while still an exciting new realm, isn’t as widely accessible as AR. For starters, you need pricey new gadgets to play around in VR, but anyone with a smartphone and an internet connection can tap into a well-crafted AR experience.
“The biggest benefit of AR is the simplicity with which you can build on top of the existing world that a user is already familiar with to teach them new things or show them new information that was previously unavailable,” says Gal Oppenheimer, who manages Contentstack’s Solutions Architecture Team. AR has, for instance, become a huge part of our daily reality, with Zoom virtual backgrounds helping people continue to meet and work collaboratively regardless of their environment.
Speaking to Oppenheimer and Contentstack’s marketing director Varia Makagonova reveals that augmented reality is a particularly effective, forward-thinking strategy for companies in retail, museums/education, and home improvement; AR works best to convey important, relevant information to customers in a quick, intuitive way. Best of all, it’s surprisingly straightforward to implement, especially if you’re working with an experienced content management team.
Great AR needs great content
As a headless CMS, Contentstack leads the way in helping businesses create innovative content experiences. In 2020, blogs and websites are no longer the main avenues of brand communication – modern customer experiences can include everything from chatbots and apps to new types of streaming media. Contentstack helps you adapt to new technology quickly and seamlessly, no matter the platform.
“When people look at AR, they only see the end experience,” says Oppenheimer. “And what people don’t realize is really there are two pieces to an AR experience. There’s the experience the consumer sees… and that is really just a 3D model, a color map, and a rendering library.” Then there’s the content, which can require just as much attention, depending on the scope of a company’s product lineup. This is where Contentstack comes into play.
A great content platform needs to be streamlined and easy to use, especially if you’re going to be working with new channels and touchpoints like Augmented Reality applications. With the right tools, it’s easy to build a well-organized, flexible content library that can be used to power all kinds of content-rich experiences.
And when it comes to retail, that often means making sure you can easily plug in personalization and e-commerce technologies into these experiences. As Oppenheimer points out, “it doesn’t matter if you have the biggest library of content available for your AR application to use. If the customer doesn’t see the one product that they are looking for to try on or learn more about, the app has not done its job for them.”
Building and tending to a useful content experience doesn’t have to be painful, though. “We have customers that have well over 2 million products in their Contentstack,” Oppenheimer says. “And when they do a release, sometimes that’s 200 products going live the same day… being able to facilitate that process easily, and then making sure that content appears in the mobile application that has all the rich AR content at the end, that’s where we come in.”
Posted by AGORACOM-JC
at 7:22 AM on Wednesday, October 28th, 2020
ELSE rapidly expands distribution to provide nationwide product availability in retail, Amazon.com and Else’s e-store
Company expects to begin its initial store distribution via KeHE Distributors in western and southern regions of the United States as early as late November 2020
To include up four regional accounts and one national key account, totaling 380 stores in advance of the Christmas season.
“We are very encouraged with the aggressive interest we have received for our product. Parents and families have waited a long time for a plant-based alternative to dairy-based baby nutrition….” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else.
VANCOUVER, BC , Oct. 28, 2020 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (” Else ” or the ” Company “), a commercial stage developer of plant-based alternatives to dairy-based baby nutrition, is pleased to provide an update on upcoming availability of the Company’s products in U.S. retail stores.
The Company expects to begin its initial store distribution via KeHE Distributors in western and southern regions of the United States as early as late November 2020 , and is to include up four regional accounts and one national key account, totaling 380 stores in advance of the Christmas season.
U.S. Retail Distribution and Rollout
Following the recent successful e-store and Amazon launch for its plant-based toddler nutrition line, Else has been working diligently through its network of retail brokers and KeHE Distributors on strategic ‘Brick & Mortar’ account listings across various critical US regions.
“We are very encouraged with the aggressive interest we have received for our product. Parents and families have waited a long time for a plant-based alternative to dairy-based baby nutrition. Soon parents across the United States will be able to find our product at stores near them in addition to being able to order online,” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 5:12 PM on Tuesday, October 27th, 2020
R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union
“We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.
Herzliya, Israel and Calgary, Alberta–(October 27, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union.
Innocan Israel, a wholly owned subsidiary of the Company, with its patent-pending unique formulation “Relief & Go CBD Spray” combines the known benefits of active ingredients such as Menthol and Camphor with CBD and Magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals.
Innocan Israel’s CTO, Mr. Nir Avram has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Nir consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.
Nir is Vice President of Research & Development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to this he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perrigo.
“We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.
About Innocan
Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
Innocan Pharma Corporation Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable
Posted by AGORACOM-JC
at 8:18 AM on Tuesday, October 27th, 2020
For the period beginning July 1st , 2020 and ending September 30th , 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products
VANCOUVER, BC , Oct. 27, 2020 – Hollister Biosciences Inc.(CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona, is pleased to provide an update on its Q3, 2020 performance.
Q3 2020 Update
For the period beginning July 1 st , 2020 and ending September 30 th , 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.
“We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners. We hope to continue this positive momentum into year-end” stated Carl Saling , CEO.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Posted by AGORACOM-JC
at 5:35 PM on Monday, October 26th, 2020
Further to its press release dated October 6, 2020, it has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its common shares on the TSX
“This is a significant milestone for the Company,” said P. Peter Pascali, CEO and Chair of PyroGenesis
Final approval of the listing is subject to the Company fulfilling all of the requirements of the TSX, including the completion of the Company’s public offering for which it has filed a preliminary prospectus on October 20, 2020
MONTREAL, Oct. 26, 2020 – PyroGenesis Canada Inc. (TSX-V: PYR; OTCQB: PYRNF; FRA: 8PY) (the “Company” or “PyroGenesis”), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and products, is pleased to announce that, further to its press release dated October 6, 2020, it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and list its common shares on the TSX.
“This is a significant milestone for the Company,” said P. Peter Pascali, CEO and Chair of PyroGenesis. “We are proud to have been conditionally accepted by Canada’s largest and most credible exchange. Having spent just under 10 years on the TSX Venture Exchange (whom we would like to thank for providing us the ideal forum on which we could attract the capital to finance our growth), we believe it is time for us to graduate to the TSX, the premier destination for publicly traded companies. This represents another step in management’s efforts to broaden our appeal to a larger shareholder base while at the same time raising the Company’s profile in the investment community. It underscores our long-term commitment to increasing investor awareness and generating shareholder value. As we continue to successfully execute our growth strategy, the graduation to the TSX should enhance the liquidity of our stock and enable us to continue building long-term shareholder value.”
Final approval of the listing is subject to the Company fulfilling all of the requirements of the TSX, including the completion of the Company’s public offering for which it has filed a preliminary prospectus on October 20, 2020. Upon, and subject to, receipt of final TSX approval, PyroGenesis’ common shares would be delisted from the TSXV and begin trading on the TSX under the symbol “PYR”.
Separately, the Company is pleased to announce the creation of a new Board position; Lead Independent Director. We are happy to announce that Mr. Robert Radin has agreed to be the Company’s first Lead Independent Director.
In an unrelated matter, the Company also announces today that it has granted stock options to acquire 200,000 common shares of the Company to Mr. Rodney Beveridge, Director, and 50,000 Common Shares to Ms. Rodayna Kafal, Director & Vice President, Investor Relations and Strategic Business Development. The stock options have an exercise price of $4.00 per common share and are exercisable over a period of five (5) years. The options are granted in accordance with the Company’s stock option plan.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com .
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the proposed graduation of the Company to the TSX and the benefits thereof on liquidity and ability to build long-term shareholder value, the execution of the Company’s growth strategy and the closing and timing of the Company’s previously announced public offering. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, including under “Risk Factors” in the Company’s most recent annual information form, which filings can be found under the Company’s profile at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the TSX nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PyroGenesis Canada Inc. For further information please contact: Rodayna Kafal, Vice President, Investor Relations and Strategic Business Development, Phone: (514) 937-0002, E-mail: [email protected] RELATED LINK: http://www.pyrogenesis.com/
